Status:

RECRUITING

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

Lead Sponsor:

University of Massachusetts, Worcester

Collaborating Sponsors:

Intra-Cellular Therapies, Inc.

Conditions:

Schizophrenia

Schizo Affective Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated level...

Detailed Description

This is a 12-week study in which we investigate how adjunctive lumateperone affects lipid particle size and body composition in clozapine-treated patients with schizophrenia; in addition, we will inve...

Eligibility Criteria

Inclusion

  • Meets the DSM-5 criteria for diagnoses of schizophrenia or schizoaffective disorder based on the MINI International Neuropsychiatric Interview (MINI 7.0)
  • On clozapine treatment for at least 6 months
  • Stable dose of antipsychotic treatment for at least 1 month
  • Well established compliance with outpatient medications
  • Subjects of child-bearing potential are required to practice appropriate birth control methods during the study.

Exclusion

  • Psychiatrically unstable per clinical judgement by the principal investigator
  • Patients not on stable dose of antipsychotic medications
  • Currently meets DSM-5 criteria for any substance use disorder other than caffeine and nicotine
  • Significant, unstable medical conditions including severe cardiovascular, hepatic, renal or other medical diseases
  • History of a seizure disorder
  • Pregnancy or breastfeeding
  • On lumateperone treatment in the past 3 months
  • On a dopamine partial agonist antipsychotic agent in the past 3 months (aripiprazole, brexpiprazole, cariprazine)

Key Trial Info

Start Date :

April 2 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2026

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06174116

Start Date

April 2 2024

End Date

November 1 2026

Last Update

May 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UMass Chan Medical School

Worcester, Massachusetts, United States, 01655

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | DecenTrialz